JP2008529486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008529486A5 JP2008529486A5 JP2007553650A JP2007553650A JP2008529486A5 JP 2008529486 A5 JP2008529486 A5 JP 2008529486A5 JP 2007553650 A JP2007553650 A JP 2007553650A JP 2007553650 A JP2007553650 A JP 2007553650A JP 2008529486 A5 JP2008529486 A5 JP 2008529486A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- peptide
- molecule
- fragment
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 7
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims 7
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 5
- 108010028921 Lipopeptides Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 230000003902 lesion Effects 0.000 claims 5
- 230000001613 neoplastic effect Effects 0.000 claims 5
- 101150059079 EBNA1 gene Proteins 0.000 claims 4
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims 4
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 claims 4
- 108010093013 HLA-DR1 Antigen Proteins 0.000 claims 4
- 108700037339 HLA-DR13 antigen Proteins 0.000 claims 4
- 108010063970 HLA-DR15 antigen Proteins 0.000 claims 4
- 108010064885 HLA-DR3 Antigen Proteins 0.000 claims 4
- 108010046732 HLA-DR4 Antigen Proteins 0.000 claims 4
- 108010001041 HLA-DR7 Antigen Proteins 0.000 claims 4
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims 4
- 108010016996 HLA-DRB5 Chains Proteins 0.000 claims 4
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 4
- 101150113776 LMP1 gene Proteins 0.000 claims 4
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims 3
- 108010059234 HLA-DPw4 antigen Proteins 0.000 claims 3
- -1 HLA-DR11 Proteins 0.000 claims 3
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 101100532584 Clostridium perfringens (strain 13 / Type A) sspC1 gene Proteins 0.000 claims 1
- 101150034979 DRB3 gene Proteins 0.000 claims 1
- 101150082328 DRB5 gene Proteins 0.000 claims 1
- 101100095550 Homo sapiens SENP7 gene Proteins 0.000 claims 1
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 1
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 claims 1
- 101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 claims 1
- 101100119347 Plasmodium falciparum EXP-1 gene Proteins 0.000 claims 1
- 101150098865 SSP2 gene Proteins 0.000 claims 1
- 102100031406 Sentrin-specific protease 7 Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0501198 | 2005-02-07 | ||
| FR0501198A FR2881746B1 (fr) | 2005-02-07 | 2005-02-07 | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
| PCT/FR2006/000229 WO2006082313A2 (fr) | 2005-02-07 | 2006-02-02 | Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008529486A JP2008529486A (ja) | 2008-08-07 |
| JP2008529486A5 true JP2008529486A5 (enExample) | 2009-02-26 |
| JP4972562B2 JP4972562B2 (ja) | 2012-07-11 |
Family
ID=35116028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553650A Expired - Fee Related JP4972562B2 (ja) | 2005-02-07 | 2006-02-02 | 白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090130134A1 (enExample) |
| EP (1) | EP1861418B1 (enExample) |
| JP (1) | JP4972562B2 (enExample) |
| AT (1) | ATE455791T1 (enExample) |
| CA (1) | CA2596929C (enExample) |
| DE (1) | DE602006011859D1 (enExample) |
| FR (1) | FR2881746B1 (enExample) |
| WO (1) | WO2006082313A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2174737C (en) * | 1993-10-29 | 2008-04-22 | Douglas V. Faller | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| CA2324426A1 (en) * | 1998-02-11 | 1999-08-19 | Douglas V. Faller | Compositions and methods for the treatment of cystic fibrosis |
| FR2830940B1 (fr) | 2001-10-17 | 2007-06-15 | Commissariat Energie Atomique | Procede de selection de ligands d'hla-dp4 et ses applications |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| SI2083856T1 (sl) | 2007-08-15 | 2011-02-28 | Circassia Ltd | Peptidi za desenzibilizacijo proti alergijam |
| WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
| WO2011038224A1 (en) | 2009-09-24 | 2011-03-31 | Trustees Of Boston University | Methods for treating viral disorders |
| MA33899B1 (fr) | 2009-12-08 | 2013-01-02 | Hemaquest Pharmaceuticals Inc | Procedes et regimes a faible dose pour des troubles des globules rouges |
| US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
| US9931359B2 (en) | 2012-05-08 | 2018-04-03 | The Johns Hopkins University | Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer |
| CN105555756B (zh) | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| KR20170094449A (ko) | 2014-12-23 | 2017-08-17 | 마가렛 앤 브림블 | 아미노산 및 펩타이드 접합체 및 이들의 용도 |
| CN108884020A (zh) | 2016-02-26 | 2018-11-23 | 奥克兰联合服务有限公司 | 氨基酸及肽共轭物以及共轭过程 |
| GB2567362B (en) | 2016-07-15 | 2022-04-20 | Nantkwest Inc | HDAC inhibitors for use with NK cell based therapies |
| EP3580561B1 (en) | 2017-02-12 | 2023-11-01 | BioNTech US Inc. | Hla-based methods and compositions and uses thereof |
| AU2018392884B2 (en) * | 2017-12-20 | 2021-11-11 | Glaxosmithkline Biologicals Sa | Epstein-Barr Virus antigen constructs |
| MX2021007556A (es) * | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
| BR112021024073A2 (pt) | 2019-05-31 | 2022-04-26 | Viracta Subsidiary Inc | Métodos de tratamento de cânceres associados a um vírus com inibidores de histona desacetilase |
| US20230100653A1 (en) * | 2020-02-10 | 2023-03-30 | The Johns Hopkins University | Cancer immunotherapy using transfusions of allogeneic, tumor-specific cd4+ t cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157780A1 (en) * | 1993-11-29 | 2004-08-12 | Epimmune Inc. | CTL inducing peptides from c-erb2 (HER-2/neu) |
| EP0770090A1 (en) * | 1994-07-13 | 1997-05-02 | Cornell Research Foundation, Inc. | Epstein-barr virus nuclear antigen 1 protein and its expression and recovery |
| US20020141995A1 (en) * | 1997-06-10 | 2002-10-03 | Irvin Charles G. | Method for treatment of inflammatory disease |
| AU783502B2 (en) * | 1999-11-24 | 2005-11-03 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| EP1229043A1 (en) * | 2001-01-30 | 2002-08-07 | Cyto-Barr B.V. | Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith |
| GB0214528D0 (en) * | 2002-06-24 | 2002-08-07 | Univ Aberdeen | Materials and methods for induction of immune tolerance |
| WO2004007536A2 (en) * | 2002-07-16 | 2004-01-22 | Affinium Pharmaceuticals, Inc. | Interactions of the epstein-barr virus protein ebna1, and uses thereof |
| WO2004041849A1 (en) * | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| US20040141995A1 (en) * | 2002-12-10 | 2004-07-22 | Rongfu Wang | MHC class I-restricted and MHC class II-restricted EBNA1 peptides |
-
2005
- 2005-02-07 FR FR0501198A patent/FR2881746B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-02 US US11/883,814 patent/US20090130134A1/en not_active Abandoned
- 2006-02-02 AT AT06709221T patent/ATE455791T1/de not_active IP Right Cessation
- 2006-02-02 CA CA2596929A patent/CA2596929C/fr not_active Expired - Fee Related
- 2006-02-02 JP JP2007553650A patent/JP4972562B2/ja not_active Expired - Fee Related
- 2006-02-02 DE DE602006011859T patent/DE602006011859D1/de active Active
- 2006-02-02 EP EP06709221A patent/EP1861418B1/fr not_active Not-in-force
- 2006-02-02 WO PCT/FR2006/000229 patent/WO2006082313A2/fr not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529486A5 (enExample) | ||
| Celis et al. | Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. | |
| TWI232108B (en) | Synthetic peptide vaccines for foot-and-mouth disease | |
| US4708871A (en) | Antigenically active amino acid sequences | |
| CA1194794A (en) | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom | |
| ES2318848T3 (es) | Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria. | |
| Tugyi et al. | The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide | |
| JP7090335B2 (ja) | 治療剤に対する免疫応答を除去するための改善された方法及び化合物 | |
| JP2003529319A (ja) | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 | |
| NZ703560A (en) | Method for activating helper t cell | |
| JP2005505503A5 (enExample) | ||
| JPS59500498A (ja) | １ａ型乳頭腫ウイルスゲノムのＬ１及びＬ２領域由来のＤＮＡ断片 | |
| RU2013109273A (ru) | Полипептиды, используемые для лечения и/или подавления инфекций, вызываемых вирусом гриппа | |
| JPH03501926A (ja) | 自己免疫病に関連する配列の特性決定及び検出 | |
| US4761470A (en) | Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody | |
| Nestorowicz et al. | Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites | |
| Askelöf et al. | Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. | |
| AU2011340430A1 (en) | Immune restricted peptides with increased efficacy | |
| Burt et al. | Diversity of the class II (I-Ak/I-Ek)-restricted T cell repertoire for influenza hemagglutinin and antigenic drift. Six nonoverlapping epitopes on the HA1 subunit are defined by synthetic peptides. | |
| CA2909669C (en) | Antiviral activity of gas6 inhibitor | |
| WO2003012107A1 (en) | Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof | |
| Parra-Lopez et al. | Major histocompatibility complex and T cell interactions of a universal T cell epitope from Plasmodium falciparum circumsporozoite protein | |
| JPH06321808A (ja) | Ｈｉｖ主要中和決定基の新規な実施態様 | |
| GB2128621A (en) | Polypeptides useful in vaccination against enteroviruses | |
| CA2139517A1 (en) | Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes |